Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

New York Valves 2025 - Echocardiographic outcomes from the TRISCEND II substudy reinforce the effectiveness of TTVR compared to medical therapy alone at one year post transcatheter tricuspid valve replacement (TTVR).

Dr Paul Grayburn (Baylor Scott and White Research Institute, Dallas, US) joins us to discuss echocardiographic outcomes one year post TTVR from the TRISCEND II substudy which evaluated the safety and effectiveness of the Edwards EVOQUE TTVR system with optimal medical therapy.

Findings showed that TTVR with the EVOQUE system showed a marked reduction in tricuspid regurgitation severity, RV reverse remodeling and reduced signs of venous congestion and significant improvements in forward stroke volume and cardiac output.

Interview Questions:
1. What is the reasoning behind the substudy?
2. What was the study design and patient population?
3. What are the key outcomes?
4. How should these findings impact clinical practice?
5. What further research is needed in this area?

Recorded remotely from Dallas, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographer:

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on X:

Чтобы скачать видео "NY Valves 25: Echocardiographic Outcomes from TRISCEND II Substudy" передвинте ползунок вправо